GIGYF2 (GRB10 Interacting GYF Protein 2), also known as TIF2 (Transcriptional Intermediary Factor 2), is a large scaffold protein encoded by the GIGYF2 gene on chromosome 5q33.21. This protein plays critical roles in insulin-like growth factor (IGF) signaling, neurodevelopment, and has been implicated in Parkinson's disease pathogenesis. GIGYF2 serves as a molecular scaffold that integrates multiple signaling pathways, particularly those involving the IGF-1 receptor and insulin receptor signaling cascades.
The protein's name derives from its ability to interact with GRB10 (Growth Factor Receptor Bound Protein 10), an adapter protein that negatively regulates IGF-1 and insulin signaling. Through this interaction, GIGYF2 modulates downstream PI3K/AKT and MAPK/ERK pathways, influencing cell growth, survival, and metabolic homeostasis. The discovery of GIGYF2 mutations in familial Parkinson's disease has generated significant interest in understanding its normal physiological functions and how dysregulation contributes to neurodegeneration.
| Property |
Value |
| Gene Symbol |
GIGYF2 |
| Gene Name |
GRB10 Interacting GYF Protein 2 |
| Aliases |
TIF2, GYF-2, Periphilin, TNRC15 |
| Chromosomal Location |
5q33.2 |
| Genomic Coordinates |
Chr5:156,765,521-156,974,498 (GRCh38) |
| NCBI Gene ID |
26060 |
| Uniprot ID |
Q9NYV4 |
| Ensembl ID |
ENSG00000146670 |
| OMIM ID |
612003 |
| Gene Type |
Protein coding |
| Total Exons |
39 |
| Transcript Length |
7.8 kb |
| Protein Length |
2,443 amino acids |
¶ Protein Structure and Biochemistry
GIGYF2 is a large protein consisting of approximately 2,443 amino acids with a molecular weight of around 270 kDa. The protein contains several distinctive structural features that mediate its diverse cellular functions:
¶ Domain Architecture
- N-terminal Region (1-400 aa): Contains multiple YGFF (Gly-Tyr-Phe-Phe) repeat motifs, which are characteristic of glycine-phenylalanine-rich proteins involved in protein-protein interactions. These repeats may mediate interactions with RNA-binding proteins and transcriptional regulators.
- Central Region (400-1500 aa): Harbors multiple protein-protein interaction domains including coiled-coil regions that facilitate dimerization and complex formation with signaling proteins
- C-terminal Region (1500-2443 aa): Contains nuclear localization signals (NLS) and potential transactivation domains, suggesting a role in transcriptional regulation
Bioinformatic analyses predict several functional features:
- Coiled-coil domains: 8 predicted coiled-coil regions throughout the protein
- Nuclear localization signals: 3 predicted NLS sequences in the C-terminal region
- Disordered regions: Multiple intrinsically disordered regions, typical of scaffold proteins
- Phosphorylation sites: Over 50 potential phosphorylation sites for various kinases
GIGYF2 undergoes several post-translational modifications:
- Phosphorylation: Multiple serine/threonine phosphorylation sites, particularly in the central region. AKT, PKC, and CK2 have been predicted to phosphorylate GIGYF2
- Sumoylation: Potential SUMO modification sites that regulate nuclear-cytoplasmic trafficking and protein stability
- Ubiquitination: Involved in protein turnover and degradation pathways, regulated by E3 ubiquitin ligases
GIGYF2 functions as a critical scaffold in the IGF-1 receptor signaling pathway, which is essential for neuronal survival and function. This pathway is particularly important in the brain, where IGF-1 acts as a neurotrophic factor promoting neuronal differentiation, synaptic plasticity, and protection against various insults.
- GRB10 Binding: GIGYF2 binds to the SH2 domain of GRB10 through its C-terminal region, forming a ternary complex with the IGF-1 receptor. This interaction is critical for modulating downstream signaling intensity
- PI3K/AKT Pathway Modulation: The GIGYF2-GRB10 complex regulates PI3K recruitment to the activated IGF-1 receptor, controlling AKT phosphorylation and downstream pro-survival signaling. AKT activation leads to phosphorylation of BAD, GSK-3beta, and FOXO transcription factors
- MAPK/ERK Pathway: GIGYF2 also influences RAS-MAPK signaling, affecting cell proliferation and differentiation through ERK1/2 activation
- Cell Growth: Modulates IGF-1 mediated cell growth and proliferation in neural progenitor cells
- Cell Survival: Regulates AKT-dependent anti-apoptotic signaling, protecting neurons from various stressors
- Metabolic Control: Influences insulin sensitivity and glucose metabolism in the brain and peripheral tissues
- Protein Synthesis: Through mTORC1 activation, regulates synaptic protein synthesis required for plasticity
¶ Neuronal Function and Neurodevelopment
In the central nervous system, GIGYF2 plays vital roles in neurogenesis, synaptic plasticity, and neuronal maintenance. These functions are essential for proper brain development and cognitive function throughout life.
- Neural Progenitor Cells: GIGYF2 expression in neural stem cells regulates proliferation and differentiation, with highest expression during embryonic development
- Brain Development: Critical for proper cortical development and neuronal migration through modulation of IGF-1 signaling gradients
- Dopaminergic Neurons: Specifically important for the survival and function of dopaminergic neurons in the substantia nigra pars compacta, which are selectively vulnerable in Parkinson's disease
- Synaptic Plasticity: Involved in activity-dependent synaptic modifications including long-term potentiation (LTP) and depression (LTD)
- Dendritic Arborization: Regulates dendritic growth and branching through cytoskeletal reorganization
- Synaptic Transmission: Modulates neurotransmitter release through presynaptic mechanisms involving calcium regulation
Beyond development, GIGYF2 continues to function in the adult brain, particularly in neurogenic niches:
- Hippocampal Stem Cells: Regulates proliferation in the subgranular zone of the dentate gyrus
- Subventricular Zone: Controls olfactory bulb neurogenesis
GIGYF2 has been implicated in Parkinson's disease (PD) susceptibility through multiple genetic studies. The identification of GIGYF2 as a PARK locus (PARK11) has stimulated research into its role in dopaminergic neuron survival.
- Lautier et al. (2008): First reported GIGYF2 mutations in familial PD patients, identifying missense variants in approximately 5% of early-onset families. This landmark study established GIGYF2 as the gene underlying the PARK11 locus
- GWAS Findings: Subsequent genome-wide association studies have identified GIGYF2 variants as modest risk factors for sporadic PD, though effect sizes are generally small (odds ratio 1.1-1.3)
- Meta-analyses: Combined analyses confirm association, particularly in European and Asian populations
| Mutation Type |
Examples |
Pathogenic Relevance |
| Missense |
p.Q1108H, p.R1340C, p.L1705P |
Loss of function, impaired signaling |
| Nonsense |
p.S1526X, p.R1565X |
Truncated protein |
| Frameshift |
c.2386delC, c.5632_5633del |
Null allele |
| Splice Site |
c.3018+1G>A, c.4535-2A>G |
Aberrant splicing |
GIGYF2 variants impair IGF-1 mediated neuroprotection in dopaminergic neurons. This represents the primary mechanism by which GIGYF2 mutations may contribute to PD pathogenesis:
- Reduced AKT Activation: Mutant GIGYF2 fails to properly scaffold GRB10, leading to decreased PI3K/AKT signaling. This reduces phosphorylation of pro-survival targets like BAD and FOXO3a
- Increased Apoptosis: Loss of pro-survival signaling renders neurons more vulnerable to cellular stress including oxidative damage, mitochondrial toxins, and protein aggregates
- Mitochondrial Dysfunction: Altered IGF signaling affects mitochondrial dynamics, biogenesis, and quality control through effects on PGC-1alpha and related pathways
- Complex I Deficiency: GIGYF2 dysfunction may contribute to mitochondrial Complex I impairment observed in PD substantia nigra
- PINK1/PARKIN Pathway: Cross-talk between IGF signaling and mitophagy pathways; GIGYF2 variants may sensitize neurons to mitophagy defects
- ATP Production: Impaired energy metabolism in dopaminergic neurons leads to cellular dysfunction and eventual death
- Autophagy Regulation: IGF-1 signaling modulates autophagy, which is crucial for clearing misfolded proteins including alpha-synuclein
- ER Stress: Altered protein folding and ER stress response in neurons with GIGYF2 variants
- Lysosomal Function: Connection to GBA-associated PD risk through shared lysosomal pathways
PD patients with GIGYF2 variants typically present with:
- Typical Parkinsonism: Bradykinesia, resting tremor, rigidity - clinically indistinguishable from idiopathic PD
- Age of Onset: Often early to mid-onset (50-65 years), though late-onset cases are reported
- Disease Progression: Variable, generally similar to idiopathic PD
- Treatment Response: Levodopa-responsive in most cases
- Non-motor Symptoms: Sleep disturbances, olfactory dysfunction, and constipation may precede motor symptoms
| Gene |
Function |
Interaction with GIGYF2 |
| SNCA |
Alpha-synuclein |
Shared protein homeostasis pathways |
| LRRK2 |
Leucine-rich repeat kinase 2 |
Parallel kinase pathways affecting neurite outgrowth |
| PARK2 (Parkin) |
E3 ubiquitin ligase |
Mitochondrial quality control |
| PINK1 |
Mitochondrial kinase |
Mitophagy regulation |
| GBA |
Glucocerebrosidase |
Lysosomal function |
| TMEM175 |
Lysosomal potassium channel |
Lysosomal homeostasis |
| DNAJC13 |
Co-chaperone |
Endosomal trafficking |
- IGF-1/PI3K/AKT Pathway: Primary pathway modulated by GIGYF2; controls neuronal survival
- Insulin Receptor Signaling: Metabolic effects; connects peripheral metabolism to brain function
- RAS/MAPK Pathway: Cell growth and differentiation; involved in neurogenesis
- mTOR Pathway: Protein synthesis and autophagy; regulates synaptic plasticity
Modulating GIGYF2 function or its downstream pathways represents a potential therapeutic strategy for PD. While direct targeting of GIGYF2 itself remains challenging, downstream pathway modulation offers therapeutic opportunities.
- IGF-1 mimetics: Agents that activate IGF-1 receptor independent of GIGYF2, bypassing the defect
- AKT activators: Direct AKT pathway activators bypassing IGF-1/GIGYF2 to restore pro-survival signaling
- GRB10 antagonists: Small molecules that disrupt GIGYF2-GRB10 interaction to relieve pathway inhibition
- AKT-enhancing compounds: Phosphatidylinositol analogs that promote AKT membrane localization
- mTOR modulators: Rapamycin and analogs for autophagy induction to clear protein aggregates
- Mitochondrial protectants: CoQ10, creatine, and related compounds to support energy metabolism
- Gene Therapy: Viral vector-mediated GIGYF2 delivery to restore proper function
- Small Molecule Screens: Identify compounds that restore GIGYF2 function or compensate for its loss
- Biomarker Development: GIGYF2 expression or phosphorylation as PD progression marker
- Combination Approaches: Targeting multiple pathways simultaneously for synergistic effects
Beyond PD, GIGYF2 has been implicated in several neurodevelopmental conditions. These associations highlight its essential role in brain development and function.
- Genetic Findings: Rare GIGYF2 variants identified in ASD patients through whole exome sequencing studies
- Functional Studies: Mutations impair synaptic function and dendritic morphology in neuronal models
- Brain Development: Altered cortical development observed in model systems
- De Novo Mutations: Loss-of-function variants identified in ID patients
- Cognitive Phenotype: Variable intellectual impairment ranging from mild to severe
- Associated Features: Sometimes with epilepsy, motor delays, or facial dysmorphism
- Association Studies: GIGYF2 variants show modest association in some populations
- Neurobiological Mechanisms: Altered IGF signaling affects neurotransmitter systems implicated in schizophrenia
- Treatment Implications: Potential for targeted interventions affecting GABAergic and glutamatergic signaling
- GIGYF2 Knockout: embryonic lethal around E9.5, highlighting essential developmental role
- Conditional Knockout: Dopaminergic neuron-specific deletion leads to progressive motor deficits
- Mutant Mice: Transgenic mice with PD-associated mutations show vulnerability to MPTP
- Morpholino Studies: GIGYF2 knockdown disrupts dopaminergic neuron development
- CRISPR Models: Zebrafish models recapitulate key features of PD including dopaminergic neuron loss
- Patient-derived iPSCs: Neurons from patients with GIGYF2 variants show altered stress responses
- CRISPR-edited Lines: Isogenic lines with mutations for disease modeling
- Indicated Patients: Early-onset PD, family history, atypical features
- Testing Methods: NGS panels, whole exome sequencing, targeted sequencing
- Variant Interpretation: ACMG guidelines for pathogenicity assessment
- Confirmatory Diagnosis: Establishes genetic etiology in ambiguous cases
- Family Counseling: Informs recurrence risk for family members
- Precision Medicine: Potential for targeted therapies in the future
GIGYF2 shows widespread expression in the brain:
| Region |
Expression Level |
Cell Type |
| Cerebral Cortex |
High |
Neurons, astrocytes |
| Hippocampus |
High |
Pyramidal cells, interneurons |
| Substantia Nigra |
Moderate-high |
Dopaminergic neurons |
| Cerebellum |
Moderate |
Purkinje cells, granule cells |
| Basal Ganglia |
Moderate |
Medium spiny neurons |
- Developmental Stage: Highest expression during embryonic development
- Cellular Stress: Upregulated by oxidative stress and mitochondrial dysfunction
- Hormonal Regulation: Estrogen and IGF-1 modulate expression